Chemocentryx reported $-30550000 in EBITDA for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Alnylam Pharmaceuticals ALNY:US USD -247440000 65.85M
Amgen AMGN:US USD 3.5B 62M
AstraZeneca AZN:LN USD 3.6B 404M
Bayer BAYN:GR EUR 2.45B 2.31B
Biogen BIIB:US USD 992.8M 82.9M
Biomarin Pharmaceutical BMRN:US USD 27.91M 36.51M
Bristol Myers Squibb BMY:US USD 5.32B 456M
GlaxoSmithKline GSK:LN GBP 3.36B 916M
Glaxosmithkline GSK:US GBP 3.36B 916M
Johnson & Johnson JNJ:US USD 7.81B 876M
Macrogenics MGNX:US USD -22111000 16.82M
Mirati Therapeutics MRTX:US USD -185727000 9.22M
Novartis NOVN:VX USD 4.69B 34M
Omeros OMER:US USD -50446000 13.2M
Pfizer PFE:US USD 10.52B 2.78B
Sarepta Therapeutics SRPT:US USD -120652000 80.59M
Takeda 4502:JP JPY 272.27B 36.53B
Teva Pharmaceutical TEVA:IT USD 1.06B 31M
YTE INCY:US USD 134.94M 141.85M